Major trial launches for first chikungunya vaccine

NCT ID NCT07467707

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: Bavarian Nordic Source: ClinicalTrials.gov ↗

First seen Mar 12, 2026 · Last updated May 15, 2026 · Updated 9 times

Summary

This study tests an experimental vaccine to prevent chikungunya, a mosquito-borne virus that causes fever and joint pain. About 6,144 adolescents and adults will receive either the vaccine or a placebo. The goal is to see if the vaccine can stop the disease and reduce long-term joint problems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Kamphaeng Phet Provincial Hospital

    Kamphaeng Phet, Changwat Kamphaeng Phet, 62000, Thailand

    Contact

  • Songklanagarind hospital, Prince of Songkla University (PSU)

    Hat Yai, Changwat Songkhla, 90110, Thailand

    Contact

  • WRAIR-AFRIMS Philippines, Cebu (WRAIR-APC)

    Cebu City, Cebu, 6000, Philippines

    Contact

Conditions

Explore the condition pages connected to this study.